



Inside this Issue

2026 50th Anniversary Annual Meeting Update from the MSTS President	1
Fellowship Committee	4
Communications and Technology Committee	4
Skeletal Metastasis Committee	4
Research Committee	5
Musculoskeletal Tumor Registry Update	6
Guidelines and EBM Committee	6
Advocacy Task Force	7
Donate through OREF	7
MSTS Welcome Our New Members . . .	8
Thank You Donors!	8
SarcomaStrong Corner	9
MSTS Executive Committee	10
Future Meetings - Save the Dates! . .	11

2026 50th Anniversary Annual Meeting Update from the MSTS President



Francis Hornicek, Jr., MD, PhD
Program Chair



Brooke Crawford, MD
Program Co-Chair



Nicola Fabbri, MD
Program Co-Chair



Francis Y. Lee, MD, PhD
MSTS President



Celebrating 50 Years!
J.W. MARRIOTT TURNBERRY HOTEL
October 29-31, 2026

We hope you will join us for our Annual Meeting taking place October 29–31, 2026, at the JW Marriott Turnberry in Miami. **Early-Bird Discounted Registration Pricing:** We are offering an early bird discounted rate for our Annual Meeting registrants until **July 31st, 2026** (does not apply to residents, non-surgeons, or research assistants, as they are already discounted). **With early bird registration, you will also get early access to the discounted hotel room block** at the JW Turnberry (link will be provided in your registration confirmation). **Registration will close on October 7. Register today!**



A Family-Friendly Conference Center (J.W. Marriott Turnberry, Miami, Florida): The hotel property offers multiple optional offerings, including Tidal Cove Waterpark (slides, lazy river, Kids' Cove, FlowRider), supervised Kids Club, daily children's programming, family golf, pickleball/padel, family wellness activities, multiple pools, and family-friendly dining options. Families visiting during late October can also enjoy seasonal Halloween events, pumpkin patches, and family-friendly fall festivals throughout the Aventura/Miami area. MSTS will offer treat bags for children in attendance. Kids 12 and under are free to attend the social event and welcome reception. Yoga, fitness, Zumba, and Pilates classes are available. The 3,600-square-foot fitness center features extensive circuit training, upper and lower body strength machines, and ample free weights. Golf practice facility use with unlimited range balls is included in the resort fee.




MSTS Headquarters

1515 E. Woodfield Road
Suite 345
Schaumburg, IL 60173
info@msts.org
847/698-1625



CONFERENCE GRANT
Department of Health and Human Services
National Institutes of Health

Notice of Award Federal Award Date
FAIN# R13AR087326 05/27/2026




Principal Investigator(s):
Francis Young-In Lee, MD

NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES

2026 MSTs-NIAMS-NCI R13 Early-Stage Investigator Award

Reception Honoring MSTs ESIs, J.W. Marriott Turnberry, 6 pm, Oct 28, 2026



 Julia Visgauss Duke U	 Joshua Lawrenz Vanderbilt U	 Zachary Burke Cleveland C	 Michael Colello Vanderbilt U	 Drew Ormseth U Minnesota	 Duncan Ramsey Oregon HSU	 Alex Christ UCLA	 Ahmed Aoude McGill U
 Christopher Collier Indiana	 Anthony Bozzo McGill U	 Alexander Lazarides Moffit CC	 Stephen Chenard Vanderbilt	 David Clever WASU	 Ana Belzarena U Missouri	 Joseph Ippolito Rutgers U	



NATIONAL CANCER INSTITUTE



National Institute of Arthritis and Musculoskeletal and Skin Diseases

J.W. Marriott Turnberry
Miami, Florida, USA
Oct 29-31, 2026

NEW The NIAMS-NCI-MSTS R13 Traveling Awards

The 2026 MSTs Annual Meeting is partly supported by the National Institute of Arthritis, Musculoskeletal and Skin Disorders (NIAMS) and the National Cancer Institute (NCI) to foster MSTs Early-Stage Investigators (ESIs). [Congratulations to MSTs ESIs who submitted outstanding work and received the NIAMS-NCI-MSTS R13 Traveling Awards.](#)

OREF is thrilled to support MSTs Early Stage Investigators and 50th Anniversary MSTs Annual Meeting

Orthopaedic Research and Education Foundation (OREF) was in 1955 and has supported numerous MSTs members for their research, enhanced patient care, education, and career advancement. Many MSTs members donated to OREF.

Recipients of the OREF grants span from the Founders of the MSTs to current MSTs members, including Drs. Henry J. Mankin, William Enneking, John Healey, Regis O'Keefe, Francis Y. Lee, Eric Henderson, Bang Hoang, Michelle Ghert, Cynthia Emory, Ben Miller, David Geenenberg, Kurt Weiss, Nicholas Bernthal, and many others.



NEW Technology Innovation Course, Miami Anatomic Research Center, October 28, 2026

The MSTs is planning to host a hands-on technical course for current fellows and MSTs members at the Miami Anatomy Research Center, 8850 NW 20th St. Doral, Florida 33172-2602, USA, on October 28, 2026. Experienced MSTs instructors will teach many commonly used implant techniques and cadaveric procedures. Check the [MSTs website](#) for registration details.

Continued on page 3

2026 50th Anniversary Annual Meeting Update, cont'd from pg. 2

NEW Scientific Sessions

Categories: Bone Tumors
Soft Tissue Tumors
Skeletal Metastases
Science
Interactive Case Discussions
Multi-disciplinary Tumor Board
Early-Stage Investigator Sessions

Special Sessions

- Career and Practice Development for Early-Stage Investigators
- Grantsmanship & Real-Time NIH Mock Study Section
- Molecular & Immuno-Oncology
- Disasterplasty

NEW Invited Expert Talks

(Confirmed Speakers, Subject to Change)

- **David Clever, MD**
Tumor Microenvironment
- **Bang Hoang, MD** Growth Factors & Kinases in Musculoskeletal Tumors
- **Robin Jones, MD** (CTOS President)
Targeting Cell Death & Survival Signaling in Sarcomas
- **Regis O'Keefe, MD** Orthopedic Oncology Clinician Scholarly Pathways
- **Kurt Weiss, MD** How to Get Musculoskeletal Oncology Research Grants?
- **Nathan Mesko, MD** Developing Clinical Proficiency in Your First Job
- **Nicholas Bernthal, MD** Building Academic Practice and Career
- **Brian Snyder, MD, PhD** (OREF, ORS, POSNA) Predicting Pathologic Fracture Risk: Translating Biomechanics to Clinical Practice
- **Michelle Ghert, MD** Clinical Trial Tutorial in the Real World
- **Julia Visgauss, MD** (ESI) Application of DNA and RNA Sequencing to MSK Oncology
- **Christopher Collier, MD** (ESI) Metastatic Cancer-Bone-Muscle Interactions
- **Ran Wei, MD** Minimizing Complications in Pelvic Resection: Traditional Incision & Approach
- **Shintaro Iwata, MD, PhD** Management of High-Grade Soft Tissue Sarcoma: Without Adjuvant Radiation

- **Jay Wunder, MD** Management of High-Grade Soft Tissue Sarcoma: With Adjuvant Radiation Therapy
- **Pietro Ruggieri, MD**
Onco-Ortho-Plastic Procedure
- **Panos Papagelopoulos, MD** Resection and Reconstruction of the Shoulder
- **Xiadong Tang, MD**
En Bloc Spondylectomy
- **Francis J. Hornicek, Jr, MD, PhD**
Breakthrough Molecular Oncology of Chordoma
- **Francis Y. Lee, MD, PhD**
Pushing the Limit of 'Orthopaedic Interventional Oncology'
- **International Presidents: Robin Jones, MD** (CTOS), **Yang-Guk Chung, MD** (APMSTS), **Michiel van de Sande, MD** (EMSOS), **Marcos Galli, MD** (SLATME President), **Ricardo Becker, MD** (Brazil), and **Peter Steadman, MD** (ISOLS)

NEW Fundraising Golf Event

A special fundraising golf event will take place at the J.W. Marriott Turnberry Soffer Golf Course on October 28, 2026, from 8:00 am to 1:00 pm. The fund will be used for Sarcoma Research and the Research Publication Fund for the MSTs Members. For those who are interested in playing or fundraising, please send an email inquiry to francis.lee@yale.edu. Golf practice facility use with unlimited range balls is included in the resort fee.

NEW Industry Innovation Symposia

Learn from Industry Innovators for advanced patient care! Representatives and designated speakers of the Diamond-Level Industry Partners will share the most exciting new developments.



Fellowship Committee – Santiago Lozano Calderón, MD, PhD, Chair

The spring of 2026 brought to completion another successful fellowship match cycle. A total of 18 programs (11 ACGME accredited, 5 MSTs recognized and 2 without any recognition status) offered 25 positions of which 23 were filled. Also, this summer, we approach the completion of the first year of the use of the New Innovations platform to log cases and perform program evaluations for programs that are MSTs recognized. We are planning to expand in the use of this platform to uniformly evaluated MSTs recognized programs in terms of case volume and distribution, curriculum, faculty structure and academic activities. Feedback from fellowship applicants and Program Directors highlighted the difficulties to set up interview dates and review applications

without a set schedule.

This year, we will pilot a uniform time schedule for all programs. Applications for fellowship will close on November 16th, 2026. A period for evaluation of candidates and applications will be established between November 17th to December 15th, 2026. Universal date for release of interview invitations will be December 16th, 2026 with a subsequent interview period starting on December 18th, 2026. We hope this timetable will help candidates and programs to prevent interview date conflicts and facilitates the process to all parties.

In very exciting news, we will be offering, with the support of Zimmer, \$25,000

Fellowship grants for MSTs recognized or ACGME accredited programs. Stay tuned for eligibility criteria and deadlines for application in 2026.

Lastly, we invite you to participate this coming October 28th, 2026 in our Innovation Course taking place in Miami before our Annual Meeting. The venue is the Miami Anatomical Research Center (MARC) located in Miami. A very comprehensive course with 4 tracks of education (Pediatric Oncology, Percutaneous Pelvis, Megaprosthesis and Open pelvic Surgery) will be offered with access to cadaver lab and multiple educational sessions with member of our society. Please visit the [Annual Meeting Website](#) for Registration.

Communications and Technology Committee – Cecilia Belzarena, MD, Chair

The Communications Committee continues to focus on expanding the visibility, engagement, and impact of MSTs by promoting member activities, educational opportunities, advocacy efforts, and society initiatives across multiple communication platforms.

Over the past several months, a major area of focus has been supporting promotion of the upcoming MSTs Annual Meeting. Through coordinated social media campaigns, email communications, and website updates, we have worked to maintain strong awareness and engagement surrounding meeting registration, abstract notifications, key deadlines, venue highlights, and attendee experience. We were particularly encouraged by the strong interaction across our social platforms and continued enthusiasm from members as planning for this milestone meeting progresses.

Our I'm Your Orthopaedic Oncologist campaign remains an important initiative to highlight the people behind our specialty and showcase the breadth, diversity, and impact of musculoskeletal oncology. These profiles continue to receive positive engagement and help strengthen connections across career stages while increasing

awareness of our field among trainees, colleagues, patients, and the broader orthopaedic community.

Advocacy has also remained a priority. Recent communications efforts have focused on raising awareness around challenges in access to specialty musculoskeletal oncology care and encouraging members and patients to share experiences that may help inform future advocacy initiatives. We remain committed to supporting MSTs's voice in areas that impact patient access and delivery of care.

Beyond social media, the committee continues to coordinate and distribute the monthly MSTs e-blast and seasonal newsletter communications to ensure members remain informed of important MSTs updates. We have actively promoted educational webinars, grant and funding opportunities, committee initiatives, career opportunities, and job postings relevant to our membership.

Our website continues to serve as a central communication hub and is updated regularly with meeting information, educational content, webinars, committee announcements, and member resources. We also continue to expand and promote

patient-facing educational materials through the Patients' Topics Library and Conditions We Treat sections, supporting our goal of improving accessible educational resources for patients and families.

The Communications Committee remains committed to highlighting the outstanding work occurring across MSTs committees and creating opportunities for broader member engagement. We encourage members to continue sharing ideas, submitting content, engaging with our communications channels, and helping amplify the voice of MSTs.

Thank you to all committee members, contributors, and MSTs leadership for your continued collaboration and support.

Research Committee – Bang Hoang, MD, Chair

The Research Committee (RC) has been highly productive during the latter part of 2025 and the spring of 2026. We would like to recognize the outstanding contribu-

tions of the following RC members: Anthony Bozzo, Elyse Brinkmann, Ian Dickey, Eric Henderson, Takashi Hirase, Josh Lawrenz, and Brian Walczak, whose expertise,

dedication, and positive energy continue to strengthen the committee's efforts.

Sarcoma Strong Grant 2026 Cycle

A new Request for Applications (RFA) for Sarcoma Strong applications was released on January 22, 2026, following extensive input and collaboration from the MSTs Board and the RC. The RFA included the following funding opportunities:

Sarcoma Strong Mentored Award
(\$25,000. Deadline March 23, 2026)

Sarcoma Strong Research Award
(\$50,000. Deadline March 23, 2026)

We thank many members of our society who submitted applications, including high-quality basic, translational, and clinical research proposals aimed at advancing the diagnosis, treatment, and outcomes of both pediatric and adult sarcomas. The RC

continues to benefit from the expertise of members with extensive NIH experience. The committee convened a formal review panel on May 9, 2026, during which each application underwent rigorous peer review. Every proposal was evaluated by at least two independent reviewers with no conflicts of interest and subsequently discussed by the full panel to ensure a thorough and equitable review process.

We are pleased to announce that David Clever of Washington University has been selected as the recipient of the STL Cure Sarcoma Research Award for his proposal entitled, "Targeting DNMT3B in Chondrosarcoma." We also extend our congratulations to Alexander Lazarides of the Moffitt

Cancer Center, along with his mentors, **Everett Moding** and **John Mullinax**, for receiving the Mentored Research Award for their proposal entitled, *"Establishing a Perioperative ctDNA Platform to Detect Residual Disease After Resection of Localized High-Risk Soft Tissue Sarcoma."*

These outstanding projects exemplify the high caliber of research being conducted by MSTs members and underscore our shared commitment to advancing sarcoma science and improving patient outcomes

We look forward to following the progress of their work and extend our sincere best wishes to Drs. Clever, Lazarides, Moding, and Mullinax as they pursue their respective research endeavors.

MSTS Early-Stage Investigator Enrichment Program

The MSTs Early-Stage Investigator (ESI) Enrichment Program is designed to support the development of future independent investigators in musculoskeletal oncology by providing structured mentorship, research training, and resources to generate preliminary data. Reflecting MSTs's commitment to career development, the program aims to prepare early-stage members for impactful translational, clinical, and technology-driven research in sarcoma and other musculoskeletal tumors.

Developed in response to feedback from the MSTs Open Mic Session on Research at the January 21, 2026 Board Meeting and subsequently approved by the MSTs Board, the program will be offered annually through 2028 and is structured to emphasize mentor–mentee partnerships. By fostering meaningful collaborations within and beyond MSTs, the program is intended to position participants for long-term success in translational research, clinical trials, and emerging areas such as molecular oncology,

novel therapeutics, and advanced technologies. Program funds may be utilized over a three-year period.

The RC looks forward to receiving a strong and highly competitive pool of applications from early-career MSTs members and is excited to support the next generation of investigators in advancing the field of musculoskeletal oncology. The application deadline for this program is **July 15, 2026**.

AAOS Specialty Society Research Support Fund

For the 2026 funding cycle, the RC recently released an internal program announcement on April 10 in response to a new RFA issued by the AAOS. The eligibility was expanded to include all MSTs members, encompassing both early-career investigators and established researchers who have

previously secured major extramural funding. Following a competitive internal review process, the RC selected the submission from PI Michelle Ghert at McMaster Univ. titled *Proximal Femur Reconstruction or Internal Fixation For Metastases (PERFORM) Randomized Controlled Trial*.

A strong pool of high-quality submissions and impactful research ideas were proposed by our membership. These applications reflect the continued commitment of MSTs investigators to advancing musculoskeletal oncology research and improving patient outcomes.

Building Competitive Grants and a Sustainable Research Program

To foster the development of the next generation of MSTs investigators in clinical, translational, and basic science research, the RC partnered with a distinguished group of accomplished researchers to host

a grant preparation and research career development workshop at the 2025 MSTs Annual Meeting in Mexico City. Designed to enhance participants' understanding of grant development and submission while

providing guidance on building a sustainable and successful research career, the session targeted junior and mid-career faculty, fellows, and residents with an interest in

Continued on page 6

Building Competitive Grants and a Sustainable Research Program, cont'd from pg. 5

research. Through practical advice, mentorship, and discussion, attendees gained valuable insights into navigating the increasingly competitive research funding environment. The workshop was convened on December 3, 2025. The faculty included:

Michelle Ghert (McMaster University)
Eric Henderson (Dartmouth)
Bang Hoang (Montefiore Einstein)
Kevin Jones (University of Utah)
Regis O'Keefe (Washington University)
Rick Terek (Brown University)
Kurt Weiss (University of Pittsburgh)

The workshop was exceptionally well received and provided attendees with valuable perspectives on grant writing, research strategy, and career development. The RC is grateful to the faculty for generously sharing their expertise and to all participants for their enthusiastic engagement. We look forward to offer similar educational and professional development opportunities in the future.

The RC remains committed to providing timely, rigorous grant reviews and meaningful educational opportunities that sup-

port the professional growth and research success of our membership. We hope that these initiatives continue to enhance the experience and engagement of MSTs members while advancing the society's research mission. We welcome feedback and suggestions on how we can further improve our programs, processes, and member experience. Please feel free to reach out to any member of the Research Committee through info@msts.org. We appreciate your continued support and participation and look forward to seeing everyone in Miami.

Musculoskeletal Tumor Registry (MsTR) Update – Adam Levin, MD

The first few years of the Musculoskeletal Tumor Registry (MsTR) were largely spent building infrastructure and establishing initial participating centers. As the registry started to expand, the focus shifted towards ensuring data integrity. We are excited to enter the next phase of maturation for the MsTR. In recognition of this, the MsTR Steering Committee has reorganized its subcommittees. The Infrastructure and Engagement team has helped expand our Alternative Entry Pathway, which allows for streamlined data entry by using REDCap. As a result, sites can contribute the minimal dataset elements into the registry while completing their EMR

build for the rest of the automated fields. This has been an important development for site expansion. Now, with 29 sites in active contracting, the MsTR is poised to capture a large segment of the tertiary musculoskeletal oncology care centers. In addition, the team continues to develop the toolbox to assist new sites with information about IRB applications and onboarding, in order to facilitate contributing patient information.

The Grants and Funding team is working towards a major grant proposal which aims to leverage the patient-reported outcome measures within the registry.

Meanwhile, the Grants and Publications team has worked closely with the Registry Analytics team at the AAOS to dive into the findings. These have yielded multiple manuscripts either accepted or in revisions, as well as upcoming presentations at the ISOLS Meeting in Vienna. A big thanks for all the hard-working members of the MsTR Steering Committee, our partners at the AAOS Family of Registries, the participating centers across the US, and the patients and families for their invaluable contribution towards understanding our patient outcomes better.

Guidelines and Evidence Based Medicine Committee – Yee-cheen Doung, MD, Chair

I appreciate the trust you've given me in chairing this committee after having been a member for the past 4 years. Thanks to Nicholas Tedesco for guiding us these past three years.

Our previous novel clinical practice assessments (NCPAs) are still on our website. We have decided to put the NCPAs on pause for this calendar year and possibly for the next calendar year.

In 2023, Dr. Gordon Guyatt gave an enlightening keynote address at our an-

nual meeting on the evolution of clinical research and the implementation of evidence based medicine¹. One of the many highlights was the implementation of a decision aid such that patients had more of an understanding of what each element of the shared decision making process would affect them. As a result, we have decided to create one that could be used for our members. Our first attempt will be regarding the treatment of high-grade soft tissue sarcomas and the risks and benefits to adjuvant therapy and the timing of such therapy.

We would like to invite the membership for any additional thoughts or ideas for decision aids, clinical practice guidelines, or quality improvement projects. Please do not hesitate to reach out to me or to any of our committee members: Matthew Colman, Alexander Lazarides, Dipak Ramkumar, Samir Sabharwal, and Brianna Siracuse.

Advocacy Task Force – Kelly Homlar, MD, Chair

The Advocacy Task Force and the Practice Management Committee will merge to form the Health Policy Committee. This new committee is charged with providing comprehensive, timely, and actionable analysis of health policy issues affecting musculoskeletal oncology patients and providers.

The committee will be organized into three subcommittees:

Legislative: Monitors federal and state legislation that may affect musculoskeletal oncology practice and patient care; engages with members of Congress; submits letters of support or opposition on relevant legislation; supports the AAOS OrthoPAC; participates in the AAOS National Orthopaedic Leadership Conference (NOLC) and Hill Day; and engages in AAOS Advisor Circle activities.

Regulatory: Monitors CMS payment and coverage policies and works with the AMA and related bodies, including the RUC and CPT Editorial Panel, on issues related to reimbursement, valuation, coding, compliance, quality, outcomes, registries, and practice management.

External Relations: Coordinates MSTs health policy efforts with other professional societies involved in sarcoma care, develops and maintains relationships with patient advocacy organizations, and serves as a liaison to the MSTs Communications Committee to disseminate relevant health policy information to members and patients.

Advocacy remains one of the core pillars of MSTs. The creation of the Health Policy

Committee will strengthen our ability to engage in the health policy arena, advance initiatives that benefit our patients and practices, and protect the physician-patient relationship.

The Advocacy Taskforce hosted its second Advocacy Webinar in March, which focused on key regulatory issues affecting musculoskeletal oncology practices. Discussion topics included the Medicare Physician Fee Schedule, CMS payment reform initiatives, quality reporting requirements, and emerging alternative payment models. Understanding these policies is critical to ensuring that musculoskeletal oncology care is appropriately valued, reimbursed, and accessible to the patients we serve. We thank all members who participated and look forward to future educational and advocacy initiatives. The recorded webinar is available on the website.

We continue to address barriers to musculoskeletal oncology care at both the state and federal levels. Members have reported an increasing number of patients who are referred only to find out they are out of network. Efforts to obtain network-gap exceptions are often time-consuming and frequently unsuccessful. When access is denied, patients may be required to travel several hours to distant in-network providers despite the availability of qualified specialists closer to home. These delays increase financial burden, disrupt family support systems, and create additional challenges for medically vulnerable patients undergoing chemotherapy, radiation therapy, or surgery. These barriers are not theoretical—they are actively delay-

ing care and adversely affecting patient outcomes.

A group consisting of an MSTs member, a referring physician who has experienced delays in obtaining timely orthopaedic oncology care for several patients, a Georgia State Senator who is a retired orthopaedic surgeon, and leadership from the Medical Association of Georgia recently met with the Georgia Insurance Commissioner to highlight this growing access-to-care issue.

As members of the AAOS Advisors Circle, we are also working closely with AAOS Office of Government Relations (OGR) staff and advocacy leaders, including Dr. Joel Mayerson, current AAOS Advocacy Council Chair, to bring national attention to this problem. The issue was specifically highlighted in AAOS comments submitted to CMS regarding the Medicare Advantage Technical Rule on January 26, 2026. Additional advocacy efforts are planned, including a focused Washington, DC fly-in this fall, and AAOS OGR is developing a member toolkit with practical guidance on requesting network gap exceptions, engaging state insurance commissioners, and navigating insurance barriers to specialty care.

Please continue to share patient stories and detailed insurance information. This is a complex issue that spans multiple insurance products and payers, and meaningful progress will require a coordinated, multifaceted advocacy strategy. Real-world examples from our members remain critical to documenting the problem and advancing solutions.

Donate through OREF



MSTs and OREF share a vision of improving care for patients through our support for high quality research.

Did you know you can support both MSTs and OREF at the same time?
Make an OREF Annual Fund gift and you can add on a gift for MSTs.


It's a quick and easy way to support two great organizations. Visit oref.org/annual.

MSTS Welcomes Our New Members

We are pleased to welcome six new members who were approved by the Executive Committee in February. In addition, we would like to recognize three members who have advanced in their careers and updated their existing MSTS membership category.

Welcome to our new members and congratulations to those members continuing to advance in their careers!

Active Members



Erik J. Geiger, MD, MHS
new member




Kim Tsoi, MD, PhD, FRCSC

Affiliate Member



Elham Nasri, MD
new member


Candidate Members



Julian Emerson Dilley, MD



Drew Ormseth, MD
new member




Brianna Siracuse, MD

**Interested in Becoming a
MSTS Member?
Ready to Advance to a New
MSTS Membership Category?**

**Membership Application Deadline:
September 1, 2026**

Details [here](#).

Resident Members



**Brandon Stephen
Gettleman, MD**
new member



Christopher Hamad, MD
new member



Divakar N. Lal, MD
new member



Thank You Donors

We would like to extend our sincere thanks to the following members and donors who have made donations to MSTS. Donations listed were credited from January 1 through June 1, 2026.

Odion Binitie, MD
Felix H. Cheung, MD
Maureen Collins

Robert Guglielmo
Rajiv Rajani, MD
William Ward, MD, FACS

Rosanna Wustrack, MD
Melissa Zimel, MD


Sarcoma Strong Corner – Matthew R. DiCaprio, MD

Our first big event in 2026 was our Sarcoma Strong Gala on March 14th in Scotia, New York. Our guest speaker was Albert Aboulafia, Musculoskeletal Tumor Society President from 2009-2010. Dr. Aboulafia embodies the theme of this year's gala which was the spirit of collaboration between the multi-disciplinary care teams

needed to treat our sarcoma patients and the hope that it offers to them knowing they are not fighting alone. Not only did he inspire our guests with his address he personally made a significant contribution to Sarcoma Strong to fund research. Thank you Al for your friendship and generosity!



Inspiring Advocacy with a New Focus on Sustainability



David Clever, MD, PhD



Alexander Lazarides, MD

Congratulations to our 2026 Sarcoma Strong Research Grant recipients David Clever, MD, PhD from Washington University in St. Louis and Alexander Lazarides, MD from Moffitt Cancer Center in Tampa.

Dr. Clever's work targeting DNMT3B as a therapeutic strategy in chondrosarcoma will be supported with a \$50,000 STL Cure Sarcoma Research Award. A collaboration that was initiated in 2024 between Sarcoma Strong and [STL Cures Sarcoma](#) has resulted in this new award we hope to see continue for several years to come. Dr. Lazarides was awarded the \$25,000 Mentored Research grant to establish a perioperative liquid biopsy workflow at Moffitt and pilot-test a ctDNA assay in adults undergoing resection of localized

high-risk soft tissue sarcomas. We look forward to their contributions to the sarcoma community.

The Sarcoma Strong Endowed Research Fund reached its goal endowment level of \$500,000 early in 2026. We anticipate funding our first \$25,000 grant from this fund in 2027. RFA to be announced towards the end of the year.

Continued on page 10

Our next focus is on growing the endowment. We want to fund higher grant levels in future years. To accomplish this, we have established an easy pathway for grateful patients or philanthropist to give directly to the endowment fund. Large gifts can be made through Zelle direct bank transfers.



Sarcoma Strong ENDOWED RESEARCH FUND

Funding Sarcoma Research Forever

A permanent investment in the future of sarcoma care

Endowment level of \$500,000 reached in 2026
Annual \$25,000 Sarcoma Research Grant beginning in 2027

Why the Endowment Matters

- Sustainable research funding
- Accelerates breakthroughs
- Creates a lasting legacy
- Impact in perpetuity
- Built to grow

Your Impact

\$1,000	Supports ongoing research funding
\$10,000	Advances annual research awards
\$25,000	Funds one year of sarcoma research

Goal: \$1,000,000 to fund an annual \$50,000 Sarcoma Research Grant

How to Give



Give via Zelle

Scan QR Code to donate directly into the Fund.

No transaction fees.

The first step is to search for your bank.

Check Payable To:

Sarcoma Strong Inc.
1367 Washington Ave.,
Albany, NY 12206

Write Endowed Research Fund in the Memo

www.sarcomastrong.com

Every gift - of any amount - moves us closer to our goal and fuels the future of sarcoma research

Monetary Gifts



Sarcoma Strong ENDOWED RESEARCH FUND

Funding Sarcoma Research Forever

A permanent investment in the future of sarcoma care

Endowment level of \$500,000 reached in 2026
Annual \$25,000 Sarcoma Research Grant beginning in 2027

Why the Endowment Matters

- Sustainable research funding
- Accelerates breakthroughs
- Creates a lasting legacy
- Impact in perpetuity
- Built to grow

Your Impact

\$1,000	Supports ongoing research funding
\$10,000	Advances annual research awards
\$25,000	Funds one year of sarcoma research

Goal: \$1,000,000 to fund an annual \$50,000 Sarcoma Research Grant

Stock Transfers & Estate Planning

Security donations

Contact your brokerage firm and let them know you would like to transfer shares of a security to the Sarcoma Strong Endowment Account at Morgan Stanley. The DTC # is 0015. Please contact Sarcoma Strong for further assistance and to obtain proper account numbers for a transfer.

Estate Planning/Estate Gifts

Check with your financial institution for what information is needed to make Sarcoma Strong a beneficiary. Then contact Sarcoma Strong to help facilitate the process.

Contact: sarcomastrong@gmail.com

www.sarcomastrong.com

Every gift - of any amount - moves us closer to our goal and fuels the future of sarcoma research

Stock Transfers and Estate Planning



MSTS Executive Committee

President

Francis Y. Lee, MD, PhD
francis.lee@yale.edu

President-Elect

Matthew R. DiCaprio MD
mdicaprio15@gmail.com

Secretary

Nicholas Bernthal, MD
NBernthal@mednet.ucla.edu

Treasurer

Felasfa Wodajo, MD
wodajo@tumors.md

Immediate Past President

Rajiv Rajani, MD
rjani@ttuhsc.edu

Past President

Benjamin Miller, MD
benjamin-j-miller@uiowa.edu

Education Committee

Ginger Holt, MD
holtginger@gmail.com

Research Committee

Bang Hoang, MD
bahoang@montefiore.org

Membership Committee

David Greenberg, MD
david.greenberg@slucare.ssmhealth.com

Members-at-Large

Lisa B. Ercolano, MD
Lisa.Ercolano@ahn.org
Alexander Lazarides, MD
Alexander.Lazarides@moffitt.org

50TH ANNIVERSARY MSTS ANNUAL MEETING

October 29 - 31, 2026

JW Marriott Turnberry Conference Center – Miami, Florida

Celebrating
50
YEARS



Francis Hornicek Jr., MD, PhD
Chair



Francis Lee, MD, PhD
President



SPECIALTY DAY 2027

Las Vegas, Nevada

March 6, 2027

7:30 am – 3:30 pm

Specialty Day Planning Committee

Alexander Lazarides, MD, Chair

Samir Sabharwal, MD, Vice Chair

James Wittig, MD, Member-at-Large

Details at www.msts.org